Yervoy – References pg 1

Article

References:1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363(8);711-723.

References:
1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363(8);711-723.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Related Content
Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.

Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

Russ Conroy
August 21st 2025
Article
Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 21st 2025
Podcast
No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

Consolidative Thoracic Radiotherapy Displays Safety, Efficacy in ES-SCLC

Roman Fabbricatore
August 21st 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 21st 2025
Podcast
The primary end point of the trial was PFS. Secondary end points included OS, ORR, and the toxicity profile of nivolumab with carboplatin/cisplatin and etoposide.

Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC

Tim Cortese
August 21st 2025
Article
Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Russ Conroy
August 21st 2025
Article